Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine® to Treat Sulfur Mustard Gas (HD) Exposure

Funding will support development activities required for supplemental biological license application (sBLA) for Leukine to treat myelosuppressive effects and restore hematopoietic and immune function after HD exposure

LEXINGTON, MA – February 17, 2022 – Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of Defense (DoD) to fund development and regulatory activities to support an sBLA of Leukine® (sargramostim, rhu-Granulocyte Macrophage Colony Stimulating Factor, “GM-CSF”) for the treatment of sulfur mustard ...

Continue Reading →